Ginger
Also sold as: Zingiber officinale · Ginger rhizome · Gingerols
A culinary rhizome studied most convincingly for nausea and several pain outcomes. Capsules, dried powder, fresh root and tea do not provide interchangeable exposures.
Longevity
Community
Not enough ratings yet: 0 of 10
Scores appear after 10 ratings, so that one or two reports can't dominate. Tried it? Your rating counts.
Research
- Longevity: No human lifespan or hard cardiovascular-event benefit is established; symptom and biomarker findings are separate outcomes, not a negative longevity RCT.
REALITY CHECK // Ginger can reduce nausea, but reduced nausea is not the same as fewer vomiting episodes. Weight changes are small and low-certainty; a small comparison with sumatriptan does not establish drug equivalence, and migraine prevention was not better than placebo.
Levels: how we grade evidence. Grey = evidence of no benefit; amber = evidence it makes this goal worse.
Ratings are self-reported by a self-selected group of users: how it felt, not proof that it works.
Check your bottle
Compare what your label says with what was used in trials. This is a trial range, not a personal prescription.
Enter the amount from your label to see the result.
How it was studied
01 // STUDIED_DOSE_RANGE
Trial context
Dried-powder studies commonly use 1-2 g/day. Primary dysmenorrhea trials used 750-2000 mg/day during the first 3-4 cycle days; pregnancy nausea trials favored less than 1500 mg/day. Metabolic trials used 1.2-2 g/day for 4-12 weeks. Exact extract amounts depend on the trial preparation.
02 // TIMING_&_MATRIX
Form and schedule
Timing depends on the symptom trial. No general fasting-versus-fed advantage is established; tea cannot substitute numerically for powder.
03 // EVALUATION_WINDOW
Outcome-specific follow-up
Acute nausea and pain studies differ from metabolic studies lasting 4-12 weeks; no established longevity trial is supplied.
04 // SAFETY_&_QUALITY_GATE
Review before use
Review pregnancy, anticoagulants, planned surgery, gallstones/biliary obstruction, active ulcer disease and severe reflux. Stop for significant GI irritation or bleeding symptoms. Heartburn, diarrhea and abdominal discomfort are common limiting effects, especially at larger amounts.
UPPER LIMIT // No numerical EFSA/NIH UL is established. About 3-4 g/day of powder is a reported research/tolerability context, not an official ceiling or extract equivalent. Pregnancy use requires individualized obstetric review.
Summary
Pregnancy-related nausea is better supported than vomiting prevention. Small pain benefits exist, but glucose findings conflict and migraine prevention was negative despite promising acute-treatment data.
Mechanism
Gingerols and shogaols affect gastric motility and inflammatory signaling. Drying changes the chemical profile, while rapid conjugation and preclinical recirculation findings complicate simple absorption claims.
Typical studied dose
Dried-powder studies commonly use 1-2 g/day. Primary dysmenorrhea trials used 750-2000 mg/day during the first 3-4 cycle days; pregnancy nausea trials favored less than 1500 mg/day. Metabolic trials used 1.2-2 g/day for 4-12 weeks. Exact extract amounts depend on the trial preparation.
Upper limit
No numerical EFSA/NIH UL is established. About 3-4 g/day of powder is a reported research/tolerability context, not an official ceiling or extract equivalent. Pregnancy use requires individualized obstetric review.
Popular stacks with Ginger
Not enough stack data yet. A combination with Ginger appears here once 5 people rate the same set.
Forms and label traps
| Form on label | Active content | Studied range / day | Absorption & GI tolerance | Verdict |
|---|---|---|---|---|
| Dried ginger rhizome powder Best for: Matching symptom trials using dried powder. |
Extract weight · marker not quantified | 750–2000 mg | The commonly studied powder delivers a variable gingerol/shogaol mixture. Heartburn and GI discomfort can increase at larger amounts. |
Studied standard [FORM // REFERENCE] Full powder mass is compared; marker content is unknown. The 750-2000 mg interval spans distinct indication-specific trials, not one universal target. |
| Standardized ginger extract Best for: Matching a specified osteoarthritis or nausea extract. |
Unstandardized: active content unknown | no comparable trial range | Characterization may improve batch consistency; novel delivery systems do not establish better clinical outcomes. Concentrated extracts can still cause GI irritation. |
Caution [FORM // CAUTION] No universal marker percentage or extract-to-powder ratio is supplied. Require the actual label and trial specification. |
| Fresh ginger rhizome Best for: Culinary use rather than numerical trial matching. |
Unstandardized: active content unknown | no comparable trial range | Chemical exposure varies; recirculation findings are preclinical and not proof of a human clinical dose. Usually tolerated in culinary use; may worsen reflux. |
Good option [FORM // GOOD] No verified fresh-to-dry conversion is provided. |
| Ginger tea / infusion Best for: A beverage with uncertain active exposure. |
Unstandardized: active content unknown | no comparable trial range | Exposure depends on material, steeping and extraction. Often tolerated, but reflux can worsen. |
Good option [FORM // GOOD] Brewed beverage mass is not dried-powder dose; no trial-equivalence conversion is justified. |
Common label traps
- TRAP_01 // A powerful fat burner
A 27-RCT meta-analysis found about 1.52 kg less weight, but certainty was very low to low; this is not a large or reliable fat-burning effect. - TRAP_02 // As effective as sumatriptan
A small comparison cannot demonstrate equivalence; acute-treatment results and prevention results differ. - TRAP_03 // Black ginger is the same plant
Black ginger is Kaempferia parviflora, a different species from Zingiber officinale. - TRAP_04 // Tea equals a capsule dose
Fresh root, infusions, powders and extracts differ in exposure; no generic conversion is validated.
Other outcomes studied
Outside the five leaderboard goals. Same evidence levels as above.
- Pregnancy nausea Strong · benefit
Twelve RCTs with 1278 women reported improved nausea (MD 1.20, 95% CI 0.56-1.84), but not a clear vomiting-episode reduction (MD 0.72, CI -0.03 to 1.46). A nonsignificant miscarriage comparison had a wide CI and does not prove absence of rare harm. Obstetric supervision remains appropriate.
PMID 24642205 PMID 24390893 PMID 31937153 PMID 35147170 - Chemotherapy nausea Limited · benefit
Pooled acute/delayed nausea and vomiting effects were nonsignificant; a subgroup at <=1 g/day for more than 4 days had less acute vomiting (OR 0.30, CI 0.12-0.79). This is an adjunct hypothesis, not a replacement for antiemetics.
PMID 36501010 PMID 31519467 PMID 38625733 PMID 23448741 PMID 36232567 - Postoperative nausea Limited · benefit
A meta-analysis improved nausea severity but not clearly vomiting incidence, combined PONV or rescue antiemetic use.
PMID 34700257 - Motion sickness Limited · benefit
Small older studies conflict; some show symptom or gastric-rhythm benefits while others do not outperform controls.
PMID 12576305 PMID 2062873 PMID 6121968 PMID 32714473 - Acute migraine Limited · benefit
A three-RCT meta-analysis reported pain freedom at 2 hours RR 1.79 (CI 1.04-3.09) and pain MD -1.27 (CI -1.46 to -1.07). Small trials do not establish equivalence to sumatriptan.
PMID 33293189 PMID 23657930 PMID 29768938 PMID 42601183 - Migraine prevention Limited · no benefit
A double-blind prevention RCT did not outperform placebo; acute benefits cannot be transferred to prevention.
PMID 31398997 - Knee osteoarthritis Moderate · benefit
Pain improved about 7.88 mm on a 100-mm VAS (CI -11.92 to -3.85): statistically significant but clinically small, with some additional mild GI effects.
PMID 32214292 PMID 25300574 PMID 22054010 PMID 35147170 - Primary dysmenorrhea Limited · benefit
Trials suggest pain relief with 750-2000 mg/day powder for the first 3-4 days; the Cochrane review is more cautious about certainty. The dossier ambiguously labels one effect metric, so that numerical estimate is not reproduced.
PMID 26177393 PMID 27000311 - Type 2 diabetes Limited · benefit
A 2024 five-study analysis of 1.2-2 g/day for 4-12 weeks found no significant pooled fasting-glucose/HbA1c effect, while other meta-analyses report improvement. Heterogeneity prevents a confident treatment claim.
PMID 39053695 PMID 35031435 PMID 42337792 - Lipids Limited · benefit
Triglyceride and total-cholesterol signals may be stronger in obese or diabetic populations; LDL/HDL findings are less consistent. Dose meta-regression is not proof of a causal optimal dose.
PMID 36786398 PMID 29747751 PMID 36165525 - Inflammatory biomarkers Limited · benefit
CRP, hs-CRP and TNF-alpha may fall, but IL-6 was nonsignificant (SMD -0.45, CI -1.29 to 0.38; I-squared 89%). Biomarker changes do not establish clinical event prevention.
PMID 32763761 PMID 32147845 PMID 34857250 PMID 41123858 - Body composition Limited · benefit
Across 27 RCTs and 1309 adults, weight WMD was -1.52 kg (CI -2.37 to -0.66), BMI -0.58 kg/m2, waist -1.04 cm and fat percentage -0.87 points; certainty was very low to low.
PMID 38261398 PMID 29393665 PMID 41101746 PMID 29193411 - Blood pressure Limited · benefit
Meta-analyses suggest modest lowering, with uncertain dose/population effects; this is not established medication replacement.
PMID 30972845 PMID 42566667 - Gastric emptying / dyspepsia Limited · benefit
Small trials suggest faster emptying and antral motility; symptom benefits are limited, and an artichoke-ginger mixture cannot isolate ginger.
PMID 21218090 PMID 26813467 PMID 30680163 - Muscle soreness Limited · benefit
Small heterogeneous studies suggest modest soreness or damage-marker improvement after unfamiliar eccentric work; performance benefit is unestablished and one trial used a botanical blend.
PMID 25787877 PMID 26793652 PMID 32848820
Reader questions
What is the safe maximum?
No official numerical UL is supplied. Powder, extract and culinary amounts differ; GI tolerance often limits larger amounts, so a trial ceiling should not become a personal target.
Can I use it during pregnancy?
Nausea trials generally used below 1.5 g/day, but this is study context, not a universal pregnancy prescription. Discuss symptoms, medicines and product choice with the obstetric team.
Does it thin blood?
Platelet mechanisms suggest caution, but a small warfarin study was negative. Review concentrated supplements, anticoagulants and surgery with the treating clinician.
Why does it worsen my stomach?
Ginger can provoke reflux, heartburn, diarrhea or oral burning despite helping nausea in other people. A severe or persistent reaction needs assessment.
Stack interactions
- Caution Warfarin / antiplatelets [CAUTION // REVIEW]
The tested healthy-volunteer warfarin regimen showed no significant INR, platelet or drug-kinetic change. Mechanistic reviews still justify caution with concentrated extracts and perioperative use.
PMID 15801937 PMID 25839871 PMID 38735483 - Caution Glucose-lowering medication [CAUTION // REVIEW]
An additive effect is possible, but glycemic meta-analyses conflict; review glucose monitoring with the prescriber rather than assume a predictable reduction.
PMID 39053695 PMID 35031435 - Caution Blood-pressure medication [CAUTION // REVIEW]
A modest possible additional pressure effect warrants monitoring, not substitution for treatment.
PMID 30972845 - Caution Turmeric / garlic / ginkgo and other antiplatelet stacks [CAUTION // REVIEW]
Overlapping platelet mechanisms are a theoretical concern, particularly when combined with anticoagulants; clinical risk at ordinary food amounts is not established.
PMID 25839871
Red flags: interactions and who should avoid it
Interactions
Possible additive glucose and blood-pressure lowering. Antiplatelet effects are theoretical, and a healthy-volunteer warfarin study did not show a significant INR, platelet or pharmacokinetic effect at the tested amounts; high-dose extracts and anticoagulant stacks still require review.
Avoid or ask a doctor first if
Review pregnancy, anticoagulants, planned surgery, gallstones/biliary obstruction, active ulcer disease and severe reflux. Stop for significant GI irritation or bleeding symptoms. Heartburn, diarrhea and abdominal discomfort are common limiting effects, especially at larger amounts.
Sources (PubMed, 51)
- A systematic review and meta-analysis of the effect and safety of ginger in the treatment of pregnancy-associated nausea and vomiting.
PMID 24642205 · 2014 · systematic review / meta-analysisTwelve RCTs with 1278 women reported improved nausea (MD 1.20, 95% CI 0.56-1.84), but not a clear vomiting-episode reduction (MD 0.72, CI -0.03 to 1.46). A nonsignificant miscarriage comparison had a wide CI and does not prove absence of rare harm. Obstetric supervision remains appropriate. The commonly studied powder delivers a variable gingerol/shogaol mixture. Full powder mass is compared; marker content is unknown. The 750-2000 mg interval spans distinct indication-specific trials, not one universal target.
- Effects of ginger for nausea and vomiting in early pregnancy: a meta-analysis.
PMID 24390893 · 2014 · systematic review / meta-analysisTwelve RCTs with 1278 women reported improved nausea (MD 1.20, 95% CI 0.56-1.84), but not a clear vomiting-episode reduction (MD 0.72, CI -0.03 to 1.46). A nonsignificant miscarriage comparison had a wide CI and does not prove absence of rare harm. Obstetric supervision remains appropriate.
- Effect of ginger in the treatment of nausea and vomiting compared with vitamin B6 and placebo during pregnancy: a meta-analysis.
PMID 31937153 · 2022 · systematic review / meta-analysisTwelve RCTs with 1278 women reported improved nausea (MD 1.20, 95% CI 0.56-1.84), but not a clear vomiting-episode reduction (MD 0.72, CI -0.03 to 1.46). A nonsignificant miscarriage comparison had a wide CI and does not prove absence of rare harm. Obstetric supervision remains appropriate.
- Orally consumed ginger and human health: an umbrella review.
PMID 35147170 · 2022 · systematic review / meta-analysisTwelve RCTs with 1278 women reported improved nausea (MD 1.20, 95% CI 0.56-1.84), but not a clear vomiting-episode reduction (MD 0.72, CI -0.03 to 1.46). A nonsignificant miscarriage comparison had a wide CI and does not prove absence of rare harm. Obstetric supervision remains appropriate. Pain improved about 7.88 mm on a 100-mm VAS (CI -11.92 to -3.85): statistically significant but clinically small, with some additional mild GI effects.
- Effects of Ginger Intake on Chemotherapy-Induced Nausea and Vomiting: A Systematic Review of Randomized Clinical Trials.
PMID 36501010 · 2022 · systematic review / meta-analysisPooled acute/delayed nausea and vomiting effects were nonsignificant; a subgroup at <=1 g/day for more than 4 days had less acute vomiting (OR 0.30, CI 0.12-0.79). This is an adjunct hypothesis, not a replacement for antiemetics.
- Efficacy of Ginger (Zingiber officinale) in Ameliorating Chemotherapy-Induced Nausea and Vomiting and Chemotherapy-Related Outcomes: A Systematic Review Update and Meta-Analysis.
PMID 31519467 · 2019 · systematic review / meta-analysisPooled acute/delayed nausea and vomiting effects were nonsignificant; a subgroup at <=1 g/day for more than 4 days had less acute vomiting (OR 0.30, CI 0.12-0.79). This is an adjunct hypothesis, not a replacement for antiemetics.
- Efficacy and Safety of Ginger on Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
PMID 38625733 · 2024 · systematic review / meta-analysisPooled acute/delayed nausea and vomiting effects were nonsignificant; a subgroup at <=1 g/day for more than 4 days had less acute vomiting (OR 0.30, CI 0.12-0.79). This is an adjunct hypothesis, not a replacement for antiemetics.
- Ginger as an antiemetic modality for chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis.
PMID 23448741 · 2013 · systematic review / meta-analysisPooled acute/delayed nausea and vomiting effects were nonsignificant; a subgroup at <=1 g/day for more than 4 days had less acute vomiting (OR 0.30, CI 0.12-0.79). This is an adjunct hypothesis, not a replacement for antiemetics.
- Efficacy and Safety of Ginger on the Side Effects of Chemotherapy in Breast Cancer Patients: Systematic Review and Meta-Analysis.
PMID 36232567 · 2022 · systematic review / meta-analysisPooled acute/delayed nausea and vomiting effects were nonsignificant; a subgroup at <=1 g/day for more than 4 days had less acute vomiting (OR 0.30, CI 0.12-0.79). This is an adjunct hypothesis, not a replacement for antiemetics.
- The preventive and relieving effects of ginger on postoperative nausea and vomiting: A systematic review and meta-analysis of randomized controlled trials.
PMID 34700257 · 2022 · systematic review / meta-analysisA meta-analysis improved nausea severity but not clearly vomiting incidence, combined PONV or rescue antiemetic use.
- Effects of ginger on motion sickness and gastric slow-wave dysrhythmias induced by circular vection.
PMID 12576305 · 2003 · randomized controlled trialSmall older studies conflict; some show symptom or gastric-rhythm benefits while others do not outperform controls.
- Effects of ginger on motion sickness susceptibility and gastric function.
PMID 2062873 · 1991 · randomized controlled trialSmall older studies conflict; some show symptom or gastric-rhythm benefits while others do not outperform controls.
- Motion sickness, ginger, and psychophysics.
PMID 6121968 · 1982 · study; design not established in dossierSmall older studies conflict; some show symptom or gastric-rhythm benefits while others do not outperform controls.
- Clinical Evaluation of the Use of Ginger Extract in the Preventive Management of Motion Sickness.
PMID 32714473 · 2020 · clinical report / other studySmall older studies conflict; some show symptom or gastric-rhythm benefits while others do not outperform controls.
- The efficacy of ginger for the treatment of migraine: A meta-analysis of randomized controlled studies.
PMID 33293189 · 2021 · systematic review / meta-analysisA three-RCT meta-analysis reported pain freedom at 2 hours RR 1.79 (CI 1.04-3.09) and pain MD -1.27 (CI -1.46 to -1.07). Small trials do not establish equivalence to sumatriptan.
- Comparison between the efficacy of ginger and sumatriptan in the ablative treatment of the common migraine.
PMID 23657930 · 2014 · randomized controlled trialA three-RCT meta-analysis reported pain freedom at 2 hours RR 1.79 (CI 1.04-3.09) and pain MD -1.27 (CI -1.46 to -1.07). Small trials do not establish equivalence to sumatriptan.
- Double-blind placebo-controlled randomized clinical trial of ginger ( Zingiber officinale Rosc.) addition in migraine acute treatment.
PMID 29768938 · 2019 · randomized controlled trialA three-RCT meta-analysis reported pain freedom at 2 hours RR 1.79 (CI 1.04-3.09) and pain MD -1.27 (CI -1.46 to -1.07). Small trials do not establish equivalence to sumatriptan.
- Ginger for the treatment and prevention of migraine headaches: a systematic review and meta-analysis of randomised controlled trials.
PMID 42601183 · 2026 · systematic review / meta-analysisA three-RCT meta-analysis reported pain freedom at 2 hours RR 1.79 (CI 1.04-3.09) and pain MD -1.27 (CI -1.46 to -1.07). Small trials do not establish equivalence to sumatriptan.
- Double-blind placebo-controlled randomized clinical trial of ginger (Zingiber officinale Rosc.) in the prophylactic treatment of migraine.
PMID 31398997 · 2020 · randomized controlled trialA double-blind prevention RCT did not outperform placebo; acute benefits cannot be transferred to prevention.
- Effectiveness of Ginger on Pain and Function in Knee Osteoarthritis: A PRISMA Systematic Review and Meta-Analysis.
PMID 32214292 · 2020 · systematic review / meta-analysisPain improved about 7.88 mm on a 100-mm VAS (CI -11.92 to -3.85): statistically significant but clinically small, with some additional mild GI effects. The commonly studied powder delivers a variable gingerol/shogaol mixture. Full powder mass is compared; marker content is unknown. The 750-2000 mg interval spans distinct indication-specific trials, not one universal target.
- Efficacy and safety of ginger in osteoarthritis patients: a meta-analysis of randomized placebo-controlled trials.
PMID 25300574 · 2015 · systematic review / meta-analysisPain improved about 7.88 mm on a 100-mm VAS (CI -11.92 to -3.85): statistically significant but clinically small, with some additional mild GI effects. Characterization may improve batch consistency; novel delivery systems do not establish better clinical outcomes. No universal marker percentage or extract-to-powder ratio is supplied. Require the actual label and trial specification.
- The use of ginger (Zingiber officinale) for the treatment of pain: a systematic review of clinical trials.
PMID 22054010 · 2011 · systematic review / meta-analysisPain improved about 7.88 mm on a 100-mm VAS (CI -11.92 to -3.85): statistically significant but clinically small, with some additional mild GI effects.
- Efficacy of Ginger for Alleviating the Symptoms of Primary Dysmenorrhea: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
PMID 26177393 · 2015 · systematic review / meta-analysisTrials suggest pain relief with 750-2000 mg/day powder for the first 3-4 days; the Cochrane review is more cautious about certainty. The dossier ambiguously labels one effect metric, so that numerical estimate is not reproduced. The commonly studied powder delivers a variable gingerol/shogaol mixture. Full powder mass is compared; marker content is unknown. The 750-2000 mg interval spans distinct indication-specific trials, not one universal target.
- Dietary supplements for dysmenorrhoea.
PMID 27000311 · 2016 · systematic review / meta-analysisTrials suggest pain relief with 750-2000 mg/day powder for the first 3-4 days; the Cochrane review is more cautious about certainty. The dossier ambiguously labels one effect metric, so that numerical estimate is not reproduced.
- The effect of oral supplementation of ginger on glycemic control of patients with type 2 diabetes mellitus - A systematic review and meta-analysis.
PMID 39053695 · 2024 · systematic review / meta-analysisA 2024 five-study analysis of 1.2-2 g/day for 4-12 weeks found no significant pooled fasting-glucose/HbA1c effect, while other meta-analyses report improvement. Heterogeneity prevents a confident treatment claim. An additive effect is possible, but glycemic meta-analyses conflict; review glucose monitoring with the prescriber rather than assume a predictable reduction.
- The effect of ginger supplementation on metabolic profiles in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials.
PMID 35031435 · 2022 · systematic review / meta-analysisA 2024 five-study analysis of 1.2-2 g/day for 4-12 weeks found no significant pooled fasting-glucose/HbA1c effect, while other meta-analyses report improvement. Heterogeneity prevents a confident treatment claim. An additive effect is possible, but glycemic meta-analyses conflict; review glucose monitoring with the prescriber rather than assume a predictable reduction.
- Meta-analysis of the effects of ginger supplementation on glycemic control, blood pressure and lipid profile in patients with type 2 diabetes.
PMID 42337792 · 2026 · systematic review / meta-analysisA 2024 five-study analysis of 1.2-2 g/day for 4-12 weeks found no significant pooled fasting-glucose/HbA1c effect, while other meta-analyses report improvement. Heterogeneity prevents a confident treatment claim.
- Effect of ginger (Zingiber officinale) intake on human serum lipid profile: Systematic review and meta-analysis.
PMID 36786398 · 2023 · systematic review / meta-analysisTriglyceride and total-cholesterol signals may be stronger in obese or diabetic populations; LDL/HDL findings are less consistent. Dose meta-regression is not proof of a causal optimal dose.
- The effect of ginger supplementation on lipid profile: A systematic review and meta-analysis of clinical trials.
PMID 29747751 · 2018 · systematic review / meta-analysisTriglyceride and total-cholesterol signals may be stronger in obese or diabetic populations; LDL/HDL findings are less consistent. Dose meta-regression is not proof of a causal optimal dose.
- The Effect of Ginger (Zingiber officinale) on Improving Blood Lipids and Body Weight; A Systematic Review and Multivariate Meta-analysis of Clinical Trials.
PMID 36165525 · 2022 · systematic review / meta-analysisTriglyceride and total-cholesterol signals may be stronger in obese or diabetic populations; LDL/HDL findings are less consistent. Dose meta-regression is not proof of a causal optimal dose.
- Effect of ginger (Zingiber officinale) on inflammatory markers: A systematic review and meta-analysis of randomized controlled trials.
PMID 32763761 · 2020 · systematic review / meta-analysisCRP, hs-CRP and TNF-alpha may fall, but IL-6 was nonsignificant (SMD -0.45, CI -1.29 to 0.38; I-squared 89%). Biomarker changes do not establish clinical event prevention.
- The effects of ginger supplementation on markers of inflammatory and oxidative stress: A systematic review and meta-analysis of clinical trials.
PMID 32147845 · 2020 · systematic review / meta-analysisCRP, hs-CRP and TNF-alpha may fall, but IL-6 was nonsignificant (SMD -0.45, CI -1.29 to 0.38; I-squared 89%). Biomarker changes do not establish clinical event prevention.
- The effects of the ginger supplements on inflammatory parameters in type 2 diabetes patients: A systematic review and meta-analysis of randomised controlled trials.
PMID 34857250 · 2021 · systematic review / meta-analysisCRP, hs-CRP and TNF-alpha may fall, but IL-6 was nonsignificant (SMD -0.45, CI -1.29 to 0.38; I-squared 89%). Biomarker changes do not establish clinical event prevention.
- Antioxidant and anti-inflammatory effects of ginger supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomised controlled trials.
PMID 41123858 · 2025 · systematic review / meta-analysisCRP, hs-CRP and TNF-alpha may fall, but IL-6 was nonsignificant (SMD -0.45, CI -1.29 to 0.38; I-squared 89%). Biomarker changes do not establish clinical event prevention.
- Ginger intervention on body weight and body composition in adults: a GRADE-assessed systematic review and dose-response meta-analysis of 27 randomized controlled trials.
PMID 38261398 · 2024 · systematic review / meta-analysisAcross 27 RCTs and 1309 adults, weight WMD was -1.52 kg (CI -2.37 to -0.66), BMI -0.58 kg/m2, waist -1.04 cm and fat percentage -0.87 points; certainty was very low to low.
- The effects of ginger intake on weight loss and metabolic profiles among overweight and obese subjects: A systematic review and meta-analysis of randomized controlled trials.
PMID 29393665 · 2019 · systematic review / meta-analysisAcross 27 RCTs and 1309 adults, weight WMD was -1.52 kg (CI -2.37 to -0.66), BMI -0.58 kg/m2, waist -1.04 cm and fat percentage -0.87 points; certainty was very low to low.
- Impact of ginger supplementation on obesity indices and Adipokine profiles in adults: A GRADE-based systematic review and dose-response meta-analysis of randomized controlled trials.
PMID 41101746 · 2025 · systematic review / meta-analysisAcross 27 RCTs and 1309 adults, weight WMD was -1.52 kg (CI -2.37 to -0.66), BMI -0.58 kg/m2, waist -1.04 cm and fat percentage -0.87 points; certainty was very low to low.
- A systematic review of the anti-obesity and weight lowering effect of ginger (Zingiber officinale Roscoe) and its mechanisms of action.
PMID 29193411 · 2018 · systematic review / meta-analysisAcross 27 RCTs and 1309 adults, weight WMD was -1.52 kg (CI -2.37 to -0.66), BMI -0.58 kg/m2, waist -1.04 cm and fat percentage -0.87 points; certainty was very low to low.
- Does ginger supplementation lower blood pressure? A systematic review and meta-analysis of clinical trials.
PMID 30972845 · 2019 · systematic review / meta-analysisMeta-analyses suggest modest lowering, with uncertain dose/population effects; this is not established medication replacement. A modest possible additional pressure effect warrants monitoring, not substitution for treatment.
- Ginger Supplementation and Blood Pressure in Adults: A GRADE-Based Systematic Review and Dose-Response Meta-Analysis of Randomized Controlled Trials.
PMID 42566667 · 2026 · systematic review / meta-analysisMeta-analyses suggest modest lowering, with uncertain dose/population effects; this is not established medication replacement.
- Effect of ginger on gastric motility and symptoms of functional dyspepsia.
PMID 21218090 · 2011 · randomized controlled trialSmall trials suggest faster emptying and antral motility; symptom benefits are limited, and an artichoke-ginger mixture cannot isolate ginger.
- The effect of ginger (Zingiber officinalis) and artichoke (Cynara cardunculus) extract supplementation on gastric motility: a pilot randomized study in healthy volunteers.
PMID 26813467 · 2016 · randomized controlled trialSmall trials suggest faster emptying and antral motility; symptom benefits are limited, and an artichoke-ginger mixture cannot isolate ginger.
- Ginger in gastrointestinal disorders: A systematic review of clinical trials.
PMID 30680163 · 2019 · systematic review / meta-analysisSmall trials suggest faster emptying and antral motility; symptom benefits are limited, and an artichoke-ginger mixture cannot isolate ginger.
- The Effects of Pre-Exercise Ginger Supplementation on Muscle Damage and Delayed Onset Muscle Soreness.
PMID 25787877 · 2015 · randomized controlled trialSmall heterogeneous studies suggest modest soreness or damage-marker improvement after unfamiliar eccentric work; performance benefit is unestablished and one trial used a botanical blend.
- Acute effects of ginger extract on biochemical and functional symptoms of delayed onset muscle soreness.
PMID 26793652 · 2015 · randomized controlled trialSmall heterogeneous studies suggest modest soreness or damage-marker improvement after unfamiliar eccentric work; performance benefit is unestablished and one trial used a botanical blend.
- Effect of a Blend of Zingiber officinale Roscoe and Bixa orellana L. Herbal Supplement on the Recovery of Delayed-Onset Muscle Soreness Induced by Unaccustomed Eccentric Resistance Training: A Randomized, Triple-Blind, Placebo-Controlled Trial.
PMID 32848820 · 2020 · randomized controlled trialSmall heterogeneous studies suggest modest soreness or damage-marker improvement after unfamiliar eccentric work; performance benefit is unestablished and one trial used a botanical blend.
- Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
PMID 15801937 · 2005 · randomized controlled trialThe tested healthy-volunteer warfarin regimen showed no significant INR, platelet or drug-kinetic change. Mechanistic reviews still justify caution with concentrated extracts and perioperative use.
- The influence of herbal medicine on platelet function and coagulation: a narrative review.
PMID 25839871 · 2015 · narrative reviewThe tested healthy-volunteer warfarin regimen showed no significant INR, platelet or drug-kinetic change. Mechanistic reviews still justify caution with concentrated extracts and perioperative use. Overlapping platelet mechanisms are a theoretical concern, particularly when combined with anticoagulants; clinical risk at ordinary food amounts is not established.
- Part 1: Management of antithrombotic medications in dermatologic surgery.
PMID 38735483 · 2025 · narrative reviewThe tested healthy-volunteer warfarin regimen showed no significant INR, platelet or drug-kinetic change. Mechanistic reviews still justify caution with concentrated extracts and perioperative use.
- Recent advances in the improvement of the bioavailability and therapeutic effect of ginger extracts and its main constituents.
PMID 41298173 · 2026 · narrative reviewCharacterization may improve batch consistency; novel delivery systems do not establish better clinical outcomes. No universal marker percentage or extract-to-powder ratio is supplied. Require the actual label and trial specification.
- Enterohepatic recirculation of bioactive ginger phytochemicals is associated with enhanced tumor growth-inhibitory activity of ginger extract.
PMID 24431413 · 2014 · preclinical animal studyChemical exposure varies; recirculation findings are preclinical and not proof of a human clinical dose. No verified fresh-to-dry conversion is provided.
Community comments
No approved comments yet. Comments are held for moderation.